Close

Seagen and RemeGen enter up to $2.6bn deal for cancer drug

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Alexion and DHL Partner for 100% Sustainable Aviation Fuel

Dublin, Alexion, AstraZeneca Rare Disease, has partnered with DHL...

Why Early Intervention Is Key To Managing Chronic Health Concerns

Proactive health management is essential for maintaining a good...

Seagen and a Chinese company, RemeGen, have signed an exclusive global licencing agreement to develop and market a new HER2-targeted antibody-drug conjugate (ADC), disitamab vedotin.

Merging Seagen’s drug-linker technology with RemeGen’s new HER2 antibody, disitamab vedotin selectively carries the anti-cancer agent monomethyl auristatin E (MMAE) into tumour cells that express HER2.

As per the deal, Seagen will pay $200m in upfront payment to RemeGen to exclusively licence rights to develop and market disitamab vedotin outside the latter’s territory.

Furthermore, RemeGen will get up to $2.4bn in potential payments on meeting certain development, regulatory and marketing milestones across various indications and products.

The deal also includes tiered royalty-based payments to RemeGen on the net product sales in the territory of Seagen. RemeGen will hold development and marketing rights of the drug in Asian markets, excluding Japan and Singapore.

Seagen will oversee the international development of disitamab vedotin while RemeGen will fund and carry out the part of global trials attributable to its territory. In addition, RemeGen will handle all clinical development and regulatory filings required in its territory.

Seagen president and CEO Clay Siegall said: “This collaboration leverages Seagen’s world-class expertise and knowledge of ADC development, manufacturing and commercialisation to maximise the potential of disitamab vedotin.

“The addition of disitamab vedotin as a late-stage asset with multiple development opportunities aligns strategically with our plans to continue expanding our global footprint and deliver meaningful therapies to patients around the world.”

In preclinical models, the drug demonstrated an increased affinity and higher internalisation rate versus trastuzumab.

Disitamab vedotin as monotherapy showed antitumour activity in clinical trials in various solid tumours such as urothelial, gastric and breast cancer.

Seagen noted that vedotin-based immunogenic cell death could distinguish this class of ADCs when merged with checkpoint inhibitors.

Last month, the National Medical Products Administration of China accepted the new drug application for disitamab vedotin in locally advanced or metastatic urothelial carcinoma.

Latest stories

Related stories

Alexion and DHL Partner for 100% Sustainable Aviation Fuel

Dublin, Alexion, AstraZeneca Rare Disease, has partnered with DHL...

Why Early Intervention Is Key To Managing Chronic Health Concerns

Proactive health management is essential for maintaining a good...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back